Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal of Medical Virology"
DOI: 10.1002/jmv.24947
Abstract: Daclatasvir, asunaprevir (ASV), and beclabuvir (BCV) are direct‐acting antivirals (DAAs) for patients with hepatitis C virus genotype 1 infection. This systematic review and meta‐analysis investigating the efficacy and safety of this three‐drug combination in HCV…
read more here.
Keywords:
combination;
analysis;
genotype infection;
meta analysis ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Gastroenterology"
DOI: 10.1007/s00535-019-01558-w
Abstract: Background and aimsThe clinical course and responsiveness to antiviral treatments differs among hepatitis B virus (HBV) genotypes. However, the cause of these differences is unclear. In the present study, we compared mRNA expression profiles in…
read more here.
Keywords:
infection;
genotype infection;
hbv genotype;
chimeric mice ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-020-00293-7
Abstract: Introduction Real-world treatment of hepatitis C virus (HCV) infection is complicated by many factors that are controlled for in the rigorous clinical trial setting. The aim of the present study was to assess the efficacy…
read more here.
Keywords:
elbasvir grazoprevir;
treatment;
genotype infection;
infection ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-020-00364-9
Abstract: The real-world virological efficacy and safety of interferon-free direct-acting antiviral (DAA) therapy with ledipasvir (LDV) plus sofosbuvir (SOF) were assessed in patients who were chronically infected with hepatitis C virus (HCV) genotype 2. A total…
read more here.
Keywords:
hepatitis;
virological efficacy;
genotype infection;
safety ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13138
Abstract: AIM The aim of the current study was to characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir-ritonavir and dasabuvir) and adjunctive ribavirin, and estimate covariate effects in a broad…
read more here.
Keywords:
phase;
ribavirin;
genotype infection;
population pharmacokinetics ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "World Journal of Gastroenterology"
DOI: 10.3748/wjg.v24.i7.852
Abstract: AIM To define predictors of functional benefit of direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) infection and liver cirrhosis. METHODS We analysed a cohort of 199 patients with chronic HCV genotype…
read more here.
Keywords:
predictors functional;
benefit;
functional benefit;
genotype infection ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Annals of hepatology"
DOI: 10.5604/01.3001.0010.7532
Abstract: BACKGROUND AND AIM Grazoprevir is an NS3/4A protease inhibitor (PI), while elbasvir is an NS5A inhibitor. We performed this meta-analysis to directly compare grazoprevir plus elbasvir and ribavirin regimen vs. grazoprevir and elbasvir without ribavirin…
read more here.
Keywords:
grazoprevir;
analysis;
treatment;
grazoprevir plus ... See more keywords